Apoptosis promoters

1. A method of treating patient with a lymphoid malignancy of B-cell origin or a small cell lung cancer, the method comprising administering to said patient a therapeutically effective amount of a compound having formula (II)

wherein

X 3 is Cl or F;

X 4 is azepan-1-yl, morpholin-1-yl, 1,4-oxazepan-4-yl, pyrrolidin-1-yl, N(CH 3 ) 2 , N(CH 3 )(CH(CH 3 ) 2 ), 7-azabicyclo[2.2.1]heptan-1-yl or 2-oxa-5-azabicyclo[2.2.1]hept-5-yl, and R 0 is

 wherein

X 5 is CH 2 , C(CH 3 ) 2 or CH 2 CH 2 ;

X 6 and X 7 are both hydrogen or are both methyl; and

X 8 is F, Cl, Br or I; or

X 4 is azepan-1-yl, morpholin-1-yl, pyrrolidin-1-yl, N(CH 3 )(CH(CH 3 ) 2 ) or 7-azabicyclo[2.2.1]heptan-1-yl, and R 0 is

X 4 is N(CH 3 ) 2 or morpholin-1-yl, and R 0 is

2. The method of claim 1 , wherein the compound having formula (II) is N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazine-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide.

3. The method of claim 1 , wherein the compound is orally administered to the patient.

4. The method of claim 1 , wherein the patient has a small cell lung cancer.

5. The method of claim 1 , wherein the patient has a lymphoid malignancy of B-cell origin.

6. The method claim 5 , wherein the lymphoid malignancy of B-cell origin is a non Hodgkin's lymphoma.

7. The method of claim 5 , wherein the lymphoid malignancy of B-cell origin is a follicular lymphoma.

8. The method of claim 5 further comprising administering a therapeutically acceptable amount of etoposide to the patent.

9. The method of claim 5 further comprising administering a therapeutically acceptable amount of vincristine to the patent.

10. The method of claim 5 further comprising administering a therapeutically acceptable amount of rituximab to the patent.